Expert Interview
Examining BioLineRx’s Motixafortide in Second Line Metastatic Pancreatic Cancer, With recent COMBAT/KEYNOTE-202 Phase 2a Data to Discuss
Ticker(s): BLRXAn oncologist with experience in treating metastatic pancreatic cancer
Please tell us about your experience as a physician. How many patients with pancreatic cancer do you see yearly? What % of patients do you treat with metastatic form?
Added By: catalin_adminWhat is the second-line of treatment that you’re currently using? How has your approach changed in recent years?
Added By: catalin_adminCan you comment on the mechanism of action for motixafortide, how it acts as an inverse agonist of CXCR4 and your view on the high-affinity, long receptor occupancy?
Added By: catalin_adminWhat treatment do you switch over to, for liver failure following metastasis?
Added By: catalin_adminWhat is your choice of treatment follow-up for unresectable stage IV metastatic PDAC patients, who had progressed following first-line gemcitabine-based therapy? What are the pros and cons, and how would motixafortide fit in the picture?
Added By: catalin_adminIs the 2 months survival gain what data usually looks like for pancreatic cancer? How do the Keynote arm median overall survival compare to other treatment options?
Added By: catalin_adminCan you comment on the disease control rate of 63.2% for motixafortide?
Added By: catalin_adminHow much of a need is there for this type of treatment? What are your hopes for the future? Are you optimistic about anything in particular?
Added By: catalin_adminHow likely would you be to use motixafortide in your practice, as second-line therapy?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
